Experienced in Glomus Jugulare Tumor

Dr. Michael A. Samuels

Radiation Oncology
Banner Cancer Center Specialists LLC
2946 E Banner Gateway Dr, 
Gilbert, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Glomus Jugulare Tumor
Banner Cancer Center Specialists LLC
2946 E Banner Gateway Dr, 
Gilbert, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Samuels is a Radiation Oncologist in Gilbert, Arizona. Dr. Samuels is rated as an Experienced provider by MediFind in the treatment of Glomus Jugulare Tumor. His top areas of expertise are Throat Cancer, Laryngeal Cancer, Sinus Cancer, Teratocarcinosarcoma, and Gastrostomy. Dr. Samuels is currently accepting new patients.

His clinical research consists of co-authoring 29 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in FL
Hospital Affiliations
Banner - University Medical Center Phoenix
Banner Gateway Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
MercyCare
  • EPO
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

BANNER CANCER CENTER SPECIALISTS LLC
2946 E Banner Gateway Dr, Gilbert, AZ 85234

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
Enrollment Status: Recruiting
Publish Date: December 24, 2024
Intervention Type: Radiation, Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Docetaxel
Study Phase: Phase 2
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients With Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Peposertib
Study Phase: Phase 1
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors
An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 15, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 1
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy
DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy
Enrollment Status: Completed
Publish Date: February 05, 2020
Intervention Type: Device
Study Phase: Not Applicable
View 9 Less Clinical Trials
Similar Doctors
Advanced in Glomus Jugulare Tumor
Dr. John J. Kresl
Radiation Oncology | Radiology
Advanced in Glomus Jugulare Tumor
Dr. John J. Kresl
Radiation Oncology | Radiology

Radiation Oncologists Of Central Arizona

4611 E Shea Blvd, Suite 120, 
Phoenix, AZ 
 (20.1 miles away)
602-441-3845
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Kresl is a Radiation Oncologist and a Radiologist in Phoenix, Arizona. Dr. Kresl is rated as a Distinguished provider by MediFind in the treatment of Glomus Jugulare Tumor. His top areas of expertise are Acoustic Neuroma, Prostate Cancer, Familial Prostate Cancer, and Pleuropulmonary Blastoma. Dr. Kresl is currently accepting new patients.

Experienced in Glomus Jugulare Tumor
Dr. Michael A. Garcia
Radiation Oncology
Experienced in Glomus Jugulare Tumor
Dr. Michael A. Garcia
Radiation Oncology

Banner Cancer Center Specialists LLC

10424 W Santa Fe Dr, 
Sun City, AZ 
 (35.4 miles away)
623-832-3400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Garcia is a Radiation Oncologist in Sun City, Arizona. Dr. Garcia is rated as a Distinguished provider by MediFind in the treatment of Glomus Jugulare Tumor. His top areas of expertise are Radiation Induced Meningioma, Atypical Teratoid Rhabdoid Tumor (ATRT), Neuroepithelioma, and Gliosarcoma. Dr. Garcia is currently accepting new patients.

Experienced in Glomus Jugulare Tumor
Dr. Lisa A. Mcgee
Radiation Oncology
Experienced in Glomus Jugulare Tumor
Dr. Lisa A. Mcgee
Radiation Oncology

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
 (14.3 miles away)
480-301-8000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lisa Mcgee is a Radiation Oncologist in Scottsdale, Arizona. Dr. Mcgee is rated as an Advanced provider by MediFind in the treatment of Glomus Jugulare Tumor. Her top areas of expertise are Breast Cancer, Angiosarcoma, Intraductal Papilloma, and Adenoid Cystic Carcinoma. Dr. Mcgee is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Samuels's expertise for a condition
ConditionClose
    View All 33 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile